These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 1789811)
41. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Coons JC Ann Pharmacother; 2002 Feb; 36(2):326-30. PubMed ID: 11847956 [TBL] [Abstract][Full Text] [Related]
42. [Treatment of high blood cholesterol in patients with coronary heart disease]. Nagai Y; Yamashita S Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049 [No Abstract] [Full Text] [Related]
43. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
44. [Efficacy of lipid reduction therapy in patients with coronary disease]. Saito S; Takayama T; Hone J; Hirayama A Nihon Naika Gakkai Zasshi; 2007 Mar; 96(3):435-40. PubMed ID: 17419407 [No Abstract] [Full Text] [Related]
45. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]. Thiery J; Seidel D Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888 [TBL] [Abstract][Full Text] [Related]
46. Beyond lipid lowering: the anti-hypertensive role of statins. Chopra V; Choksi PU; Cavusoglu E Cardiovasc Drugs Ther; 2007 Jun; 21(3):161-9. PubMed ID: 17468937 [TBL] [Abstract][Full Text] [Related]
47. The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients. Sarti C; Kaarisalo M; Tuomilehto J Drugs Aging; 2000 Jul; 17(1):33-51. PubMed ID: 10933514 [TBL] [Abstract][Full Text] [Related]
48. Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Haslinger-Löffler B Kidney Int; 2008 Sep; 74(5):553-5. PubMed ID: 18709024 [TBL] [Abstract][Full Text] [Related]
49. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Pedersen TR; Tobert JA Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485 [TBL] [Abstract][Full Text] [Related]
50. Achieving optimal lipid goals in patients with coronary artery disease. Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526 [TBL] [Abstract][Full Text] [Related]
51. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422 [TBL] [Abstract][Full Text] [Related]
52. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147 [TBL] [Abstract][Full Text] [Related]
53. The effects of lipid-lowering agents on acute renal allograft rejection. Kasiske BL; Heim-Duthoy KL; Singer GG; Watschinger B; Germain MJ; Bastani B Transplantation; 2001 Jul; 72(2):223-7. PubMed ID: 11477342 [TBL] [Abstract][Full Text] [Related]
54. Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait. Iqbal D; Khan MS; Khan MS; Ahmad S; Hussain MS; Ali M Lipids Health Dis; 2015 Mar; 14():15. PubMed ID: 25884722 [TBL] [Abstract][Full Text] [Related]
55. Relation of clinical benefit to metabolic effects in lipid-lowering therapy. Herd JA Am J Cardiol; 1998 Sep; 82(6A):22M-25M. PubMed ID: 9766344 [TBL] [Abstract][Full Text] [Related]
56. Statins: is there a need for alternative or adjunctive therapy? Shepherd J Br Heart J; 1995 Jul; 74(1):13. PubMed ID: 7662445 [No Abstract] [Full Text] [Related]